IMMUNOLOGY is a premier journal published by Wiley that has been at the forefront of the field since its inception in 1958. With an impressive impact factor and classified in the Q1 quartile for both Immunology and Allergy as of 2023, this journal is highly regarded among researchers and professionals alike. It ranks 36th out of 233 in the Medicine/Immunology and Allergy category, and 40th out of 236 in the Immunology and Microbiology segment on Scopus, placing it firmly within the top percentile of its field. The journal is dedicated to publishing high-quality research that advances our understanding of immunological processes, bridging basic science with clinical applications. Although it does not operate under an open-access model, it offers conventional access options that remain integral to the dissemination of vital immunological research. With its broad scope and commitment to scholarly excellence, IMMUNOLOGY continues to serve as an essential resource for those seeking the latest advancements in immunology, fostering innovation and collaboration among scientists globally.

JOURNAL OF EXPERIMENTAL MEDICINE, published by Rockefeller University Press, is a renowned peer-reviewed journal dedicated to advancing the field of experimental medicine since its inception in 1896. With an impressive impact factor and categorized in the Q1 quartile for Immunology, Immunology and Allergy, and Miscellaneous Medicine, this journal stands at the forefront of medical research and innovation. It provides a prestigious platform for scholars and practitioners to disseminate groundbreaking findings that drive the understanding of disease mechanisms and therapeutic strategies. While the journal is not open access, it maintains high visibility and engagement within the scientific community, fostering collaboration among researchers, professionals, and students alike. The journal's consistent ranking in the top percentiles of Scopus illustrates its significant impact and commitment to excellence in medical research.

Innate Immunity, published by SAGE Publications Ltd, serves as a vital platform for disseminating cutting-edge research in the fields of immunology, microbiology, cell biology, and infectious diseases. With an ISSN of 1753-4259 and an E-ISSN of 1753-4267, this journal has been a prominent contributor to the academic community since its inception in 1996, focusing on the innate immune response and its implications for health and disease. Holding a respectable impact factor and categorized in the Q2 and Q3 quartiles across various relevant domains, Innate Immunity ranks competitively in major databases, including Scopus, where it appears in the top 75th percentile for Infectious Diseases. Researchers and professionals are encouraged to explore its wealth of articles that are pivotal in bridging fundamental immunology with clinical applications, fostering a deeper understanding of immune mechanisms vital for combating human diseases.

TRENDS IN IMMUNOLOGY, published by CELL PRESS, stands as a premier source of insights and developments within the field of immunology. With an ISSN of 1471-4906 and E-ISSN of 1471-4981, this journal has established a strong reputation, evidenced by its prestigious status in Q1 quartiles for both Immunology and Allergy in 2023. It is ranked #13 out of 233 in the Scopus category of Medicine – Immunology and Allergy, and #16 out of 236 in Immunology and Microbiology, placing it within the top 94th and 93rd percentiles respectively. Since its inception in 1987, TRENDS IN IMMUNOLOGY has provided a critical platform for researchers, professionals, and students to access the latest advancements and integrative reviews in immunological research. The journal offers open access options, enhancing the accessibility of its high-impact content to a global audience. Researchers and practitioners rely on its pages not only for cutting-edge findings but also for comprehensive discussions that drive the future of immunology research.

Immunotherapy Advances, published by Oxford University Press, stands at the forefront of the rapidly evolving field of immunology and microbe interactions, focusing specifically on novel immunotherapeutic strategies and their clinical applications. Established in 2021, this peer-reviewed journal aims to disseminate high-quality research that contributes to the understanding and advancement of immunotherapeutic techniques, potentially transforming patient care in immunology. With a current Scopus rank of #140 out of 236 in the realm of Immunology, placing it in the 40th percentile, Immunotherapy Advances is positioned to be an integral resource for researchers, healthcare professionals, and students eager to stay updated with groundbreaking findings and methodologies. The journal is dedicated to fostering innovative discussions and collaborations, ensuring open access to vital research that influences treatment paradigms globally.

CLINICAL IMMUNOLOGY is a premier academic journal dedicated to the field of immunology, published by Academic Press Inc. Elsevier Science. With a robust impact reflected in its recent categorization as Q2 in Immunology and Q1 in Immunology and Allergy for 2023, this journal stands out as a key resource for researchers and professionals alike. Featuring a diverse array of articles from fundamental laboratory studies to advanced clinical applications, CLINICAL IMMUNOLOGY aims to disseminate significant research findings that contribute to the evolving landscape of immunological science. Its notable Scopus rankings underscore its esteemed position, with ranks of #33 and #36 in the respective categories, highlighting its commitment to high-quality scholarly work. Although not an open-access journal, it ensures access to valuable insights and developments in the immune response and related fields, making it an indispensable tool for students and professionals aiming to stay at the forefront of immunological research.

Welcome to the JOURNAL OF IMMUNOLOGY, a prestigious publication associated with the American Association of Immunologists and dedicated to advancing the field of immunology. With a rich history dating back to 1945, this journal is renowned for its high-impact research, evident in its notable 2023 Q1 rankings in both Immunology and Allergy, as well as its strong positions in Scopus rankings—Rank #68 in Immunology and Allergy and Rank #79 in Immunology and Microbiology. Although it operates on a subscription basis, its commitment to publishing cutting-edge studies ensures that it remains a vital resource for scientists, healthcare professionals, and students alike. As the journal continues to pave the way for innovative research and breakthroughs in immunological science, it facilitates a platform for dialogue and discovery among researchers and practitioners across the globe.

INFECTION AND IMMUNITY is a distinguished peer-reviewed journal published by the American Society for Microbiology, focusing on groundbreaking research in the fields of infection, immunology, microbiology, and parasitology. Established in 1971, this journal has built a robust legacy, converging years of scientific discovery with a vision towards 2024 and beyond. With an impressive Impact Factor, the journal holds significant rankings in various categories; its Q1 status in both Infectious Diseases and Parasitology underscores its high relevance and quality within the scientific community. Researchers and professionals alike will benefit from its content, as it promotes the latest advances in understanding immune responses and infectious agents, further legitimizing its place among the top quartiles of its respective fields. Access options are provided through traditional subscription models, ensuring a broad charitable dissemination of knowledge. As a pivotal resource for scholars and practitioners alike, INFECTION AND IMMUNITY stands at the forefront of microbiological and immunological research, fostering essential discourse that is crucial for advancing public health and scientific insight.

OncoImmunology is a leading peer-reviewed journal published by Taylor & Francis Inc, dedicated to advancing the understanding of the dynamic interplay between the immune system and cancer. Established in 2012 and adopting an open access model since 2020, OncoImmunology provides a platform for high-quality research disseminated globally, with a notable focus on innovative therapies and immunotherapeutic strategies aimed at improving patient outcomes. The journal boasts an impressive impact in the field, holding Q1 rankings in both Immunology and Oncology categories for 2023, and it is recognized within the top-tier journals in its domain, reflected in its Scopus ranks and percentiles. With contributions from leading experts and a wide audience of researchers, clinicians, and advanced students, OncoImmunology not only facilitates scholarly dialogue but also addresses pivotal challenges in cancer treatment, making it an essential resource for those invested in the future of oncological and immunological research.

HUMAN IMMUNOLOGY, published by Elsevier Science Inc, serves as a critical platform for disseminating research in the fields of immunology and allergy, as well as various aspects of miscellaneous medicine since its inception in 1980. With an ISSN of 0198-8859 and E-ISSN 1879-1166, this journal is pivotal for researchers and practitioners looking to advance their understanding of human immune responses and related conditions. The journal currently holds a respectable position within its field, as highlighted by its 2023 Scopus ranks—#114/233 in Immunology and Allergy and #132/236 in Immunology and Microbiology. Moreover, it maintains a Q2 quartile ranking in both Immunology and Allergy and miscellaneous Medicine, underscoring its influence and reach within the scientific community. Although it does not currently offer Open Access options, HUMAN IMMUNOLOGY remains dedicated to providing valuable insights and fostering academic discourse within its discipline, characterized by a rigorous peer-review process and a focus on innovative research trajectories.